Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain
AAM Supports Biden-Harris Administration’s 100-Day Review
Executive Summary
After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.
You may also be interested in...
Increased Transparency Key To Combating Drug Shortages, Says US Industry Alliance
The closure of a Teva manufacturing plant in California has raised concerns around access a number of medicines, something the End Drug Shortages Alliance says could be avoided through increased market transparency.
Endo Partners With US Government On Critical Medicines
Endo subsidiary Par Sterile Products will expand its Rochester, Michigan facility to begin the fill-finish manufacturing of both mRNA and adenovirus vaccines. Around three-quarters of the project’s expected $120m total costs are being funded by the US government as part of larger efforts to boost the country’s domestic supply of essential medicines.
Centrient CEO Sees New Opportunities From Astral Acquisition
Acquiring Astral SteriTech will open up significant new capabilities in sterile injectables for Centrient while also offering an opportunity to expand the reach of the Indian firm’s products through Centrient’s infrastructure, CEO Rex Clements tells Generics Bulletin in an exclusive interview.